Material Safety Data Sheet
ANSI Format

Hormone Replacement Products

Preparation Date 09-Mar-2007 **Revision Date** 31-Mar-2008 **Revision Number** 3

1. PRODUCT AND COMPANY IDENTIFICATION

Product Name	Hormone Replacement Products
Common Name	Not available
Chemical Name	Not applicable
Synonyms	Premarin, Premarin Cream, Premarin Intravenous, Premphase, Prempro, Congugated Estrogens, Medroxyprogesterone Acetate, 17ß Estratriol, Totelle, Premia, Trimegestone, Premique, Premique Low Dose, Premelle 2.5/5, Premelle Cycle 5, Gen-Medroxy, Premplus
Product Use	Pharmaceutical product
Classification	Hormones and Synthetic Substitutes
Supplier	Wyeth P.O. Box 8299 Philadelphia, PA 19101 USA. Telephone: 1-610-688-4400
Emergency Telephone Number	Chemtrec USA, Puerto Rico, Canada 1-800-424-9300 Chemtrec International 1-703-527-3887

2. HAZARDS IDENTIFICATION

Emergency Overview

This contains an active pharmaceutical ingredient that can affect body functions; handle with caution.

Appearance Pharmaceutical tablet, powder, or cream **Physical State** Solid **Odor** Odorless

Potential Physical Hazards Powders and solids are presumed to be combustible.

Potential Health Effects

Eyes	May cause mechanical eye irritation.
Skin	Not available
Inhalation	Not available
Ingestion	The most common effects may include, vaginal bleeding irregularities, change in menstrual flow, breast changes (tenderness, pain, enlargement, secretion, lumps), vaginal secretion, headache, vaginal yeast infections, changes in reproductive organs, skin rash, joint pain, diarrhea, dizziness, fatigue, nausea, vomiting, hair loss, and stomach/abdominal cramps/bloating. Increased risks of endometrial cancer, heart attack, pulmonary emboli, deep vein thrombosis, coronary heart disease, stroke, venous thromboembolism, breast cancer, ovarian cancer, dementia, gallbladder disease, mental depression, colitis, central nervous system effects. May impair fertility. May cause harm to the unborn child. Excreted in breast milk. May cause cancer. Please see Patient Package Insert for further information.
Therapeutic Target Organ(s)	Reproductive System.
	Listed by NTP and IARC. Not listed by OSHA.

Potential Environmental Effects See Section 12.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Common Name	CAS-No	Composition
Medroxyprogesterone Acetate	71-58-9	0 - 10 mg/tablet
Congugated Estrogens	12126-59-9	0.3 - 25 mg/tablet or vial or gram
Trimegestone	74531-62-5	0 - 500 mg/tablet
17ß Estradiol	50-28-2	0 - 2 mg/tablet
Inactive Ingredients	Not applicable	Remainder

4. FIRST AID MEASURES

Eye Contact In the case of contact with eyes, rinse immediately with plenty of water for 15 minutes and seek medical advice.

Skin Contact Take off contaminated clothing and shoes immediately. Wash off immediately with soap and plenty of water. If skin irritation persists, call a physician.

Inhalation Move to fresh air. Artificial respiration and/or oxygen may be necessary. If symptoms persist, call a physician.

Ingestion If symptoms persist, call a physician. Do not induce vomiting without medical advice. Never give anything by mouth to an unconscious person.

5. FIRE-FIGHTING MEASURES

Flammable Properties Presumed to be a combustible particulate solid.

Extinguishing Media

Suitable Extinguishing Media Use water spray, foam, dry chemical or carbon dioxide.
Unsuitable Extinguishing Media Do NOT use water jet.

Fire Fighting Evacuate area and fight fire from a safe distance. Cool closed containers exposed to fire with water spray. In the event of fire and/or explosion do not breathe fumes.

Hazardous Combustion Products Carbon oxides, nitrogen oxides.

Protective Equipment and Precautions for Firefighters In the event of fire, wear self-contained breathing apparatus and special protective equipment for fire fighters.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions Refer to protective measures listed in Sections 7 and 8.

Environmental Precautions Prevent product from entering drains. Local authorities should be advised if a significant spill cannot be contained.

Methods for Containment Not available

Methods for Cleaning up Take up mechanically and collect in suitable container for disposal. Clean contaminated surface thoroughly. Avoid formation of dust and aerosols.

7. HANDLING AND STORAGE

Handling For personal protection see Section 8. Handle in accordance with good industrial hygiene and safety practice. Skin should be washed after contact. Avoid formation of dust and aerosols.

Storage No special safety precautions required. Keep container tightly closed.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Common Name	**Exposure Guideline**
Medroxyprogesterone Acetate	1.5 mcg/m^3
Congugated Estrogens	0.15 mcg/m^3
Trimegestone	0.06 mcg/m^3
17ß Estradiol	0.5 mcg/m^3

Engineering Controls Apply technical measures to comply with the occupational exposure guideline. Enclose operations to prevent aerosol generation. General ventilation shall not be used as the primary control system. Isolators, fume hoods, or biological safety cabinets may be used based on a risk assessment.

Personal Protective Equipment

Eye/face Protection Provide eye protection based on risk assessment.

Skin Protection Wear nitrile or latex gloves. Wear protective garment.

Respiratory Protection Base respirator selection on a risk assessment.

General Hygiene Considerations When using, do not eat, drink or smoke. General industrial hygiene practice. Wash hands before breaks and at the end of workday.

Other Limit access to only personnel trained in the safe handling of this material. Consult a health and safety professional for specific PPE, respirator, and risk assessment guidance.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	Pharmaceutical tablet, powder, or cream	**Physical State**	Solid
Color	Various	**Odor**	Odorless
Odor Threshold	Not available		
pH	Not available		
Specific Gravity	Not applicable	**Water Solubility**	Not available
Solubility	Not applicable	**Evaporation Rate**	Not applicable
Partition Coefficient (n-octanol/water)	Not available	**Vapor Pressure**	Not applicable
Boiling Point	Not applicable	**Autoignition Temperature**	Not applicable
Flash Point	Not available	**Method**	None
Melting Point	Not available		
Flammability Limits in Air	**Upper** Not applicable	**Lower** Not applicable	
Explosion Limits	**Upper** Not applicable	**Lower** Not applicable	

10. STABILITY AND REACTIVITY

Chemical Stability Stable at room temperature.

Conditions to Avoid None under normal use.

Materials to Avoid No materials to be especially mentioned.

Hazardous Decomposition Products None under normal use.

Possibility of Hazardous Reactions None under normal use.

11. TOXICOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Acute Toxicity

Medroxyprogesterone Acetate

LD50 Oral	>6400 mg/kg rats >4000 mg/kg mice >5 g/kg dogs
Acute Dermal Irritation	Not a skin irritant.
Primary Eye Irritation	Mild eye irritant.
Sensitization	Not available

Congugated Estrogens

LD50 Oral	>5000 mg/kg rats IP 325 mg/kg rats IR 1740 mg/kg mice
Acute Dermal Irritation	Not available
Primary Eye Irritation	Severe irritation effects in rabbits.
Sensitization	Not available

Trimegestone

LD50 Oral	>2000 mg/kg rats
Acute Dermal Irritation	Not available
Primary Eye Irritation	Not available
Sensitization	Not a dermal sensitizer in guinea pigs.

17ß Estradiol

LD50 Oral	Not available
Acute Dermal Irritation	Not available
Primary Eye Irritation	Not available
Sensitization	Not available

Multiple Dose Toxicity

Medroxyprogesterone Acetate

No Toxicologic Effect Dose/Species/Study Length:	See Carcinogenicity

Congugated Estrogens

No Toxicologic Effect Dose/Species/Study Length: See Carcinogenicity

Trimegestone

No Toxicologic Effect Dose/Species/Study Length: Repeated dose months studies in rats, and monkeys did not demonstrate toxicologic effects after oral, and subcutaneous doses of 25 mg/kg/day.

17ß Estradiol

No Toxicologic Effect Dose/Species/Study Length: See Carcinogenicity

Maximum Tolerated Dose (MTD), Oral

Medroxyprogesterone Acetate

Carcinogenicity In a two-year oral study in female rats, a dose-related increase in pancreatic islet cell tumors occurred, and a decreased incidence of spontaneous mammary gland was observed in all treated groups. Dogs treated with MPA developed mammary nodules, some of which were malignant. In humans, results of a multinational case-control study in developing countries over a 9-year period indicated that the use of MPA did not increase the risk of breast cancer.

Genetic Toxicity Not mutagenic in AMES Test. Non-mutagenic in the mouse micronucleus assay.

Reproductive Toxicity Animal studies have reported no impairment of fertility in first or second generation studies.

Developmental Toxicity Studies in humans have shown that MPA may decrease intrauterine growth. No evidence of teratogenic effects.

Congugated Estrogens

Carcinogenicity In certain animal species, long-term continuous administration of estrogens increases the frequency of cancers in the breast, cervix, liver, pancreas, testes, uterus, and vagina. Results of animal studies may not apply to humans because of the general hormonal differences of sex steroids among species.

Genetic Toxicity No specific mutagenic information available.

Reproductive Toxicity No data available

Developmental Toxicity No evidence of teratogenic effects.

Trimegestone

Carcinogenicity No data available

Genetic Toxicity AMES Test :Negative- Nonmutagenic Non-mutagenic in the mouse micronucleus assay. Positive in the human lymphocyte chromosomal aberration assay.

Reproductive Toxicity In in rat studies, did not cause maternal effects at doses up to 25 mg/kg/day. Doses of 30-480 mg/kg/day caused maternal effects. Studies in rabbits resulted in maternotoxicity and fetotoxicity at doses of 40-160 mg/kg/day.

Developmental Toxicity No data available

17ß Estradiol

Carcinogenicity In mice studies, there was an increased incidence of mammary, pituitary, uterine, cervical, vaginal, testicular, lymphoid and bone tumors. In rat studies, there was an increased risk of mammary and/or pituitary tumors. In hamster studies there was a high incidence of malignant kidney tumors in males and in ovariectomized females, but not in intact females. In guinea pig studies, diffuse fibromyomatous uterine and abdominal lesions were observed.

Genetic Toxicity No evidence of mutagenicity was observed in a battery of *in vitro* and *in vivo* assays.

Reproductive Toxicity No data available

Developmental Toxicity No data available

Medroxyprogesterone Acetate

Target Organ(s) of Toxicity No data available

Congugated Estrogens

Target Organ(s) of Toxicity No data available

Trimegestone

Target Organ(s) of Toxicity No data available

17ß Estradiol

Target Organ(s) of Toxicity No data available

12. ECOLOGICAL INFORMATION

The following effects are based on the Active Pharmaceutical Ingredient.

Chemical Fate Information

Medroxyprogesterone Acetate

Mobility	Not available
Biodegradability	Not readily biodegradable.
Stability in Water	Not available
Bioaccumulation	Not available

Congugated Estrogens

Mobility	Not available
Biodegradability	Considered to be biodegradable under aerobic conditions.
Stability in Water	Not available
Bioaccumulation	Not available

Trimegestone

Mobility	Not available
Biodegradability	Not readily biodegradable.
Stability in Water	Not available
Bioaccumulation	May bioaccumulate in organisms.

17ß Estradiol

Mobility	Not available
Biodegradability	Not available
Stability in Water	Not available
Bioaccumulation	Not available

Ecotoxicity

Congugated Estrogens

Microorganisms	Inhibition > 150 mg carbon/liter
Algae	Not available
Daphnia	Not available
Fish	Not available

Medroxyprogesterone Acetate

Microorganisms	Not available
Algae	Not available
Daphnia	Not available
Fish	Not available

13. DISPOSAL CONSIDERATIONS

Waste Disposal Method Dispose of in accordance with local and national regulations.

14. TRANSPORT INFORMATION

Transport Information This material is not classified as hazardous for transport.

U.S. Department of Transport (DOT)	Not regulated
Canadian Transport of Dangerous Goods (TDG)	Not regulated
International Civil Aviation Organization (ICAO)	Not regulated
International Air Transport Association (IATA)	Not regulated
International Maritime Dangerous Goods (IMDG)/International Maritime Organization (IMO)	Not regulated
Transport of Dangerous Goods by Rail (RID)	Not regulated
Transport of Dangerous Goods by Road (ADR)	Not regulated
Transportation of Dangerous Goods via Inland Waterways (ADN)	Not regulated

15. REGULATORY INFORMATION

USA

Federal Regulations

OSHA Regulatory Status
This material is not considered hazardous by the OSHA Hazard Communication Standard (29 CFR 1910.1200)

SARA 313
Section 313 of Title III of the Superfund Amendments and Reauthorization Act of 1986 (SARA). This product does not contain any chemicals which are subject to the reporting requirements of the Act and Title 40n of the Code of Federal Regulations, Part 372.

SARA 311/312 Hazardous Categorization

Acute Health Hazard	No
Chronic Health Hazard	Yes
Fire Hazard	No
Sudden Release of Pressure Hazard	No
Reactive Hazard	No

This product does not contain any HAPs.

State Regulations

California Proposition 65
This product contains the following Proposition 65 chemicals:

Common Name	CAS-No	Type
Congugated Estrogens	12126-59-9	Cancer, Developmental Toxicity
Medroxyprogesterone Acetate	71-58-9	Cancer, developmental
17ß Estradiol	50-28-2	Cancer

Canada

Not classified

WHMIS Hazard Class
Non-controlled

European Union
In accordance with EC directives or respective national laws, the product does not need to be classified nor labeled.

16. OTHER INFORMATION

Prepared By	Wyeth Department of Environment, Health & Safety
Format	This MSDS was prepared in accordance with ANSI Z400.1-2004.
List of References	Product Package Insert
Revision Summary	Changes to Section 2

Disclaimer:
The information, data, recommendations, and suggestions appearing in this material safety data sheet (MSDS) and/or in materials regarding our active pharmaceutical ingredients (APIs) or products are based upon tests and data believed to be reliable as of the date of publication. NO REPRESENTATIONS OR WARRANTIES, EITHER EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR ANY OTHER WARRANTY IS MADE WITH REGARD TO THE INFORMATION PROVIDED IN THE MSDS, REGARDING THE API, OR THE PRODUCT TO WHICH THE INFORMATION PERTAINS. Accordingly, Wyeth will not be responsible for any damages resulting from use of, or reliance upon, this information as conditions of use are beyond our control. Users are responsible for assuring the safety of their workers and safe operating conditions, and for determining whether the API or product is suitable for their particular purposes. Users shall assume all risks of their use, handling, and disposal of the API and/or product in accordance with all appropriate and applicable regulations. This information relates only to the API or product designated herein, and does not relate to its use in combination with any other API, material, product, or process. No permission is granted for the use of any API or product in a manner that might infringe on existing patents.

End of MSDS